Pharmaceuticals News and Research

RSS

Pyridomycin turns out to be a lethal weapon against TB

Technology has made it possible to synthesize increasingly targeted drugs. But scientists still have much to learn from Mother Nature. Pyridomycin, a substance produced by non-pathogenic soil bacteria, has been found to be a potent antibiotic against a related strain of bacteria that cause tuberculosis.

4 Dec 2013

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

CTCs serve as clinical tool to determine patient’s response to chemotherapy

Scientists from Granada have demonstrated, for the first time, that detecting circulating tumour cells (CTCs) in blood and studying the presence of certain genetic markers in them is a technique that allows specialists to predict, with great precision, the response that advanced-cancer patients will have to chemotherapy, as well as the associated secondary effects they may suffer.

4 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

Study supports use of EndoBarrier Therapy for patients with type 2 diabetes and obesity

GI Dynamics, Inc. today announced findings from a new meta-analysis which describes the increasingly robust efficacy and safety profile of EndoBarrier Therapy, an endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity.

3 Dec 2013

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.

3 Dec 2013

CUMC researchers make new breakthrough in regenerative medicine

As fast-growing biotech company Rainbow Coral Corp. works to deliver new cutting-edge treatments in the field of regenerative medicine, a major new breakthrough could soon lead to growing new lungs for patients in a laboratory.

3 Dec 2013

Scientists figure out how transporters work

Researchers have tried for decades to understand the undulations and gyrations that allow transport proteins to shuttle molecules from one side of a cell membrane to the other.

3 Dec 2013

Tel Aviv University researchers discover a protein that kills bacteria

In the arms race between bacteria and modern medicine, bacteria have gained an edge. In recent decades, bacterial resistance to antibiotics has developed faster than the production of new antibiotics, making bacterial infections increasingly difficult to treat. Scientists worry that a particularly virulent and deadly "superbug" could one day join the ranks of existing untreatable bacteria, causing a public health catastrophe comparable with the Black Death.

3 Dec 2013

EMD Serono's TocopheRx to focus on development of oral FSH agonists for infertility treatment

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today the creation of TocopheRx, a Boston-based spin-off company resulting from the Entrepreneur Partnership Program launched by Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, in April 2012.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

JHL Biotech installs GE Healthcare's FlexFactory biomanufacturing platform at Hsinchu plant in Taiwan

GE Healthcare Life Sciences and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory biomanufacturing platform at JHL Biotech's Research Center and manufacturing plant in Hsinchu, Taiwan.

2 Dec 2013

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Visterra, Inc., a developer of novel therapeutics to prevent and treat major infectious diseases, today announced that it has received $8.1 million in proceeds from an upsized and final closing of its Series A financing round. The company also announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, which follows the recent appointment of Brian Pereira, M.D. as President and Chief Executive Officer of Visterra this past summer.

2 Dec 2013

Pharmaceutical industry in Asia to experience intensified competition

As Asia emerges as a major engine of global economic growth, the pharmaceutical and biotechnology industries in the region are expected to experience intensified competition. According to the Economist Intelligence Unit, regional pharmaceutical sales are expected to hit USD386bn, reflecting an annual average growth rate of more than 13%.

2 Dec 2013

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

Cell Therapeutics, Inc. today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOX (arsenic trioxide).

2 Dec 2013

Pivotal Therapeutics reports financial results for Q3 2013

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies announced its third quarter financial results and operational highlights for the three and nine months ended September 30, 2013.

30 Nov 2013

Three Umeå University researchers selected as Wallenberg Academy Fellows

Jonathan Klaminder, Christian Hedberg and Sjoerd Wanrooij have been selected as Wallenberg Academy Fellows at Umeå University. They are awarded grants between SEK 5 and 9 million each spread over five years from the largest single private investment in supporting young researchers in Sweden.

29 Nov 2013

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Patrys Limited (ASX: PAB), a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Patrys Limited, a clinical stage biotechnology company has announced that updated results from its PAT-SM6 Phase I/IIa clinical trial in multiple myeloma will be presented at the 55th American Society of Hematology Annual Meeting in New Orleans, LA on 7- 10 December 2013.

29 Nov 2013

Scientists design small synthetic molecules capable of blocking AIDS virus replication

A multidisciplinary team of scientists from Spanish universities and research centres, among which is the University of Valencia, has managed to design small synthetic molecules capable of joining to the genetic material of the AIDS virus and blocking its replication.

28 Nov 2013

Pharmaceuticals News and Research

Pyridomycin turns out to be a lethal weapon against TB

Research findings pave new ways to treat gastrointestinal disorders

CTCs serve as clinical tool to determine patient’s response to chemotherapy

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Study supports use of EndoBarrier Therapy for patients with type 2 diabetes and obesity

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

CUMC researchers make new breakthrough in regenerative medicine

Scientists figure out how transporters work

Tel Aviv University researchers discover a protein that kills bacteria

EMD Serono's TocopheRx to focus on development of oral FSH agonists for infertility treatment

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

JHL Biotech installs GE Healthcare's FlexFactory biomanufacturing platform at Hsinchu plant in Taiwan

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Pharmaceutical industry in Asia to experience intensified competition

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

Pivotal Therapeutics reports financial results for Q3 2013

Three Umeå University researchers selected as Wallenberg Academy Fellows

Patrys to present data from PAT-SM6 Phase I/IIa trial in multiple myeloma at ASH conference

Data from Patrys' PAT-SM6 Phase I/IIa trial in multiple myeloma to be presented at ASH Annual Meeting

Scientists design small synthetic molecules capable of blocking AIDS virus replication

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence